These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31768272)

  • 21. An emerging role for calcium sensitisation in the treatment of heart failure.
    Erhardt L
    Expert Opin Investig Drugs; 2005 Jun; 14(6):659-70. PubMed ID: 16004594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inotropes for the management of acute heart failure patients with renal dysfunction. Still an option?
    Rafouli-Stergiou P; Parissis JT; Anastasiou-Nana M
    Expert Opin Pharmacother; 2012 Dec; 13(18):2637-47. PubMed ID: 23170968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure.
    Bonios MJ; Terrovitis JV; Drakos SG; Katsaros F; Pantsios C; Nanas SN; Kanakakis J; Alexopoulos G; Toumanidis S; Anastasiou-Nana M; Nanas JN
    Int J Cardiol; 2012 Sep; 159(3):225-9. PubMed ID: 21481958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry.
    Mebazaa A; Motiejunaite J; Gayat E; Crespo-Leiro MG; Lund LH; Maggioni AP; Chioncel O; Akiyama E; Harjola VP; Seferovic P; Laroche C; Julve MS; Roig E; Ruschitzka F; Filippatos G;
    Eur J Heart Fail; 2018 Feb; 20(2):332-341. PubMed ID: 28990358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levosimendan: a retrospective single-center case series.
    Berry WT; Hewson RW; Langrish CJ; McKenzie CA; Barrett NA
    J Crit Care; 2013 Dec; 28(6):1075-8. PubMed ID: 23998721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Inotrope therapy in acute heart failure: a critical review of clinical and scientific evidence for levosimendan in the context of traditional treatment].
    Ambrosio G; Di Lenarda A; Fedele F; Gabrielli D; Metra M; Oliva F; Perna G; Senni M; De Maria R
    G Ital Cardiol (Rome); 2009 Jul; 10(7):422-33. PubMed ID: 19761100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical experience with levosimendan in anesthesiology and in the intensive care unit.
    Cavana M; Pignataro C; Fraticelli A; Mebazaa A
    Ital Heart J; 2003 May; 4 Suppl 2():61S-64S. PubMed ID: 14635372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term intravenous inotropes in low-output terminal heart failure?
    von Scheidt W; Pauschinger M; Ertl G
    Clin Res Cardiol; 2016 Jun; 105(6):471-81. PubMed ID: 26879807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The utility of levosimendan in the treatment of heart failure.
    Lehtonen L; Põder P
    Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levosimendan: a unique approach to the treatment of heart failure.
    Nawarskas JJ; Anderson JR
    Heart Dis; 2002; 4(4):265-71. PubMed ID: 12147186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive Comparison of the Effect of Inotropes on Cardiorenal Syndrome in Patients with Advanced Heart Failure: A Network Meta-Analysis of Randomized Controlled Trials.
    Chen WC; Lin MH; Chen CL; Lai YC; Chen CY; Lin YC; Hung CC
    J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmaco-economics of levosimendan in cardiology: a European perspective.
    Nieminen MS; Buerke M; Parissis J; Ben-Gal T; Pollesello P; Kivikko M; Karavidas A; Severino P; Comín-Colet J; Wikström G; Fedele F
    Int J Cardiol; 2015 Nov; 199():337-41. PubMed ID: 26241640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations.
    Fruhwald S; Pollesello P; Fruhwald F
    Expert Rev Cardiovasc Ther; 2016 Dec; 14(12):1335-1347. PubMed ID: 27778514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysis.
    Silvetti S; Nieminen MS
    Int J Cardiol; 2016 Jan; 202():138-43. PubMed ID: 26386941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Need for hospice and palliative care services in patients with end-stage heart failure treated with intermittent infusion of inotropes.
    López-Candales AL; Carron C; Schwartz J
    Clin Cardiol; 2004 Jan; 27(1):23-8. PubMed ID: 14743852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outpatient parenteral inotropic therapy for advanced heart failure.
    Young JB; Moen EK
    J Heart Lung Transplant; 2000 Aug; 19(8 Suppl):S49-57. PubMed ID: 11016488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
    Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
    Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
    Parissis JT; Andreadou I; Bistola V; Paraskevaidis I; Filippatos G; Kremastinos DT
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1143-50. PubMed ID: 18616411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.